Popat, R., Beksac, M., Dimopoulos, M. A., Gatt, M. E., Gay, F., Jo, J., Kapoor, P., Katodritou, E., Kortüm, K. M., Ling, S., Nagarajan, C., Suzuki, K., Qiu, L., Onishi, M., Ku, G., Dail, M., Mukherjee, N., Ross, J. A., Badawi, M. A., Fusco, M. J., Dobkowska, E., Arriola, E., Bueno, O. F., Bahlis, N. J., Iida, S., Moreau, P., Valent, J., Mateos, M. (2026). Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00924